Tremor Clinical Trial
Official title:
Investigating Cerebellar Inhibition and Its Clinical Significance in Parkinsonian Tremor and Intention Tremor
Cerebellocerebral connection plays an important function in motor control. Nowadays it can be investigated with neuroimaging and physiological methods in humans. Cerebellar inhibition (CBI) is a phenomenon showing a physiological suppression of the motor evoked potential (MEP) evoked from the motor cortex (M1) by delivering a preceding transcranial magnetic stimulation (TMS) on the contralateral cerebellum. Despite the mediated pathway is supposed to be the cerebello-dentato-thalamo-cortical (CDTC) circuit, there is no conclusive evidence. In addition, the clinical significant of CBI remains unclear. Based on our previous studies, we found that the patients with advanced tremor show an impaired Bereitschaftspotential. The findings support a notion that the patients with tremor bear dysfunction of the CDTC circuit. Intriguingly, the pathogenesis of the parkinsonian tremor is highly associated with the CDTC circuit. The "dimmer-switch" model suggests that the basal ganglia-thalamo-cortical circuit dysfunction may initiate the resting tremor, and the following CDTC circuit dysfunction will lead to the large-amplitude resting and postural tremor in Parkinson's disease (PD). The intention tremor is usually found in the patients with cerebellar degeneration, which is also relevant to the CDTC circuit dysfunction. We expect that the clinical significance of CBI and the mediated pathway of CBI will be clarified by this study.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | July 31, 2024 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: Patients meet the diagnosis of PD with resting/postural or cerebellar degeneration with intention tremor based on the established consensus criteria. Exclusion Criteria: 1. Patients with contraindication to TMS or MRI examination. 2. Impairment of cognition that leads unable to fully cooperate with the oral commands during examinations. 3. Functional III or above congestive heart failure, or cancer with distant metastasis. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Department of Neurology, China Medical University Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital | Ministry of Science and Technology, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline cerebellar inhibition (CBI) input output curve | The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
There are five TMS intensities used for the conditional cerebellar stimulation: 80%, 90%, 100%, 110% and 120% inion active motor threshold. Ten trials are recorded for each TMS intensity with a pseudorandomized order. The interval between two cerebellum-M1 TMS pairs is 8-seconds with 25% variability (i.e. 6-10 s) to reduce the prediction bias. |
baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS | |
Primary | Change from baseline functional magnetic resonance imaging | In this study we mainly adopt diffusion tensor imaging (DTI) to quantify two interested projections: the pallidothalamic pathway and the dentatothalamic pathway.
Diffusion tensor imaging of fifty gradient directions is acquired with five non-gradient (B0) images. The B-value is 1500 s/mm2, FOV = 240mm x 240mm, image matrix = 96 x 96, slice thickness = 2.5mm with zero gap. The voxel size is 2.5 x 2.5 x 2.5 mm3 isotopically. The TR was approximately 10000ms which is adjusted to match the slice number of requirements. Image acquired with axial direction, 56 slices to cover the whole brain. |
baseline (before the MRgFUS), 48-weeks after the MRgFUS | |
Secondary | Change from baseline clinical evaluations | In addition to a detailed history and neurological examinations, the clinical assessment also includes International Parkinson and Movement Disorder Society-sponsored UPDRS (MDS-UPDRS) and clinical rating scale for tremor (CRST)for the PD patients. The Scale for the Assessment and Rating of Ataxia (SARA) and CRST are adopted for the patients with cerebellar degeneration. | baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS | |
Secondary | Change from baseline gait analysis | The gait analysis system (Zeno Walkway System with PKMAS) provides detailed gait parameters including velocity, cadence, pressure and cyclogram.
Variables in gait analysis: 1.Gait initiation, 2.Level walking, 3.Gait termination. |
baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS | |
Secondary | Change from baseline surface electromyography and eye-tracking pattern | The pattern of eye-tracking and surface electromyography (SEMG) with accelerometer will be recorded to monitor the therapy outcome. The eye-tracking system (EyeLink 1000 Plus) will track eye movements regarding the target fixation, saccade, smooth pursuit and image stimuli. The multiple SEMG recording (CED Power1401) will focus on the arm and hand muscles relevant to the tremor (e.g. first dorsal interosseous, abductor pollicis brevis, extensor carpi radialis and flexor carpi radialis). The accelerometer can also reveal the mechanical information of the tremor oscillation. | baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02427646 -
Kinematic-guided BoNT-A Treatment for ET and PD Tremor
|
Phase 2 | |
Completed |
NCT01018485 -
The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
|
Phase 3 | |
Completed |
NCT02087046 -
Deep Brain Stimulation (DBS) for the Suppression of Tremor
|
N/A | |
Recruiting |
NCT05413291 -
Natural History Protocol for Movement Disorders
|
||
Recruiting |
NCT04654429 -
Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients?
|
Phase 4 | |
Recruiting |
NCT04825119 -
Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen
|
||
Recruiting |
NCT05150106 -
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
|
||
Completed |
NCT05152836 -
The Effect of Vibrotactile Stimulation on Parkinson's Tremor
|
N/A | |
Recruiting |
NCT04071847 -
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
|
||
Completed |
NCT02046863 -
Pilot Study for Automated Deep Brain Stimulation Programming
|
N/A | |
Not yet recruiting |
NCT06378619 -
Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach
|
||
Completed |
NCT03300193 -
The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease
|
N/A | |
Completed |
NCT01932463 -
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor
|
N/A | |
Recruiting |
NCT05216770 -
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
|
Early Phase 1 | |
Not yet recruiting |
NCT06174948 -
The Use of the CUE1 in People With Parkinson's Disease and Related Disorders
|
N/A | |
Completed |
NCT01093027 -
Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
|
N/A | |
Completed |
NCT00001667 -
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
|
N/A | |
Completed |
NCT00001324 -
PET Scan to Study Brain Control of Human Movement
|
||
Completed |
NCT04299087 -
Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
|
N/A | |
Recruiting |
NCT05150093 -
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
|
N/A |